Phase 3 Study of GRAd-COV2
Latest Information Update: 16 Jul 2021
At a glance
- Drugs GRAd COV2 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 16 Jul 2021 New trial record
- 12 Jul 2021 According to a ReiThera media release, phase 3 program has received a positive opinion from the European Medicines Agency and other important regulatory agencies based on a non-inferiority design with a primary immunological endpoint in comparison with a viral vectored vaccine already marketed and expect to initiate this trial as soon as possible.